The RAC 3-Pillar Trifecta, page-182

Further on Alzheimer's Disease

Citation: Pitman RT, Fong JT, Stone AL, Devito JT, Puri N (2013) FTO Knockdown Decreases Phosphorylation of Tau in Neuronal Cells; A Potential Model Implicating the Association of FTO with Alzheimer’s Disease. J Alzheimers Dis Parkinsonism 3: 125. doi: 10.4172/2161-0460.1000125

https://www.omicsonline.org/pdfdown...nal-cells-2161-0460.1000125.pdf&aid=19137

Then I found this with some related searching.

Pancreatic Cancer

https://www.spandidos-publications.com/10.3892/ol.2018.9873#

Tang X, Liu S, Chen D, Zhao Z and Zhou J: The role of the fat mass and obesity‑associated protein in the proliferation of pancreatic cancer cells. Oncol Lett 17: 2473-2478, 2019
​

Fat mass and obesity-associated (FTO) protein has been identified as a critical demethylase in regulating cellular mRNA stability by removing N6‑methyladenosine (m6A) residues in mRNA. Even though the role of FTO in body energy metabolism has been well established, its role in cancer cell homeostasis remains unclear. In the present study, by using RNA interference, it was indicated that FTO is required for pancreatic cancer cell proliferation. Knockdown of FTO resulted in compromised proliferation of pancreatic cancer cells. Furthermore, DNA synthesis was compromised, followed by an increase in apoptosis in FTO small interfering RNA (siRNA)‑treated cells. In terms of its underlying mechanism, FTO has been indicated to interact with MYC proto‑oncogene, bHLH transcription factor and to enhance its stability by decreasing its m6A level. Therefore, the aforementioned observations indicate a novel mechanism for the regulation of pancreatic cancer cells by FTO, which may provide insight on pancreatic cancer treatment strategies.


From my analysis about 4 x the incidence of AML and about 23.8% of the incidence of Breast Cancer.



DYOR. Revenue analysis is speculative. You are encouraged to do your own research.

My peak sales estimates for Breast Cancer are USD $14.12B, so at 23.8% x USD $14.12B that would make pancreatic cancer a potential USD $3.36B revenue opportunity ( works out at just over double the AML portion of  Pillar 3 ).

If Bisantrene also worked for Pancreatic Cancer based on the FTO inhibitor or FTO knockdown capability, this would push revenue potential for Bisantrene to USD $46B to USD $47B ballpark. Increase in Revenue Potential is about 8% based on my analysis and assumptions ( extrapolated based on comparison of incidence of Breast Cancer and Pancreatic Cancer ).




The 5-year survival rate for pancreatic cancer is very low. Just 11%.

https://www.canceraustralia.gov.au/...cancer/pancreatic-cancer-australia-statistics



On US statistics, 5-year survival is just 7% - the lowest of any cancer.